Search

Boulder, Colorado-based Array BioPharma is reporting today that it has hit a milestone that triggered a $1M payment from AstraZeneca to Array. The firm is developing small molecule biopharmaceuticals targeted at cancer. AstraZeneca and Array are codeveloping anti-cancer drugs, used to treat lung, pancreatic, colon, melanoma and thyroid cancer. Array BioPharma is backed by ARCH Venture Partners, Boulder Ventures, Falcon Technology Partners, Frazier Healthcare Ventures, and Rovent Limited Partnership.
posted on Monday, April 10, 2006

Related companies:
Array Biopharma

Related stories:
> Array BioPharma, VentiRx In License Deal
> Array BioPharma Gets Phase 2 Payment
> Array BioPharma Licenses Rights To Amgen
> Array BioPharma Appoints New CFO
> Array BioPharma Gets $85M From Novartis

---

Techrockies.com Home